SK Biopharmaceuticals Co., Ltd.
326030
Rangering i aksjer
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aksjekurs
$51.65
Markedsverdi
$4.05B
Endring (1 dag)
0.27%
Endring (1 år)
-30.95%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
P/B-forhold for SK Biopharmaceuticals Co., Ltd. (326030)
P/B-forhold per October 2026 TTM: 5.32
Ifølge SK Biopharmaceuticals Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 5.32. Ved slutten av 2024 hadde selskapet et P/B-forhold på 15.93.
P/B-historikk for SK Biopharmaceuticals Co., Ltd. fra 2011 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 5.32 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.93 | -44.04% |
| 2023 | 28.46 | 61.13% |
| 2022 | 17.66 | 3.07% |
| 2021 | 17.14 | -46.44% |
| 2020 | 32.00 | -105.05% |
| 2019 | -633.75 | -570.11% |
| 2018 | 134.81 | 0.30% |
| 2017 | 134.41 | 212.50% |
| 2016 | 43.01 | 22.07% |
| 2015 | 35.23 | 21.42% |
| 2014 | 29.02 | -14.39% |
| 2013 | 33.89 | 23.27% |
| 2012 | 27.50 | 16.93% |
| 2011 | 23.51 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | 17.52% |
US
|
|
| 13.2547 | 149.19% |
US
|
|
| 4.208 | -20.89% |
AU
|
|
| 6.1824 | 16.23% |
NL
|
|
| - | - |
CH
|
